These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Immune response genes receptors expression and polymorphisms in relation to multiple sclerosis susceptibility and response to INF-β therapy. Karam RA; Rezk NA; Amer MM; Fathy HA IUBMB Life; 2016 Sep; 68(9):727-34. PubMed ID: 27346865 [TBL] [Abstract][Full Text] [Related]
6. Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients. Weber F; Cepok S; Wolf C; Berthele A; Uhr M; Bettecken T; Buck D; Hartung HP; Holsboer F; Müller-Myhsok B; Hemmer B Pharmacogenomics J; 2012 Jun; 12(3):238-45. PubMed ID: 21502966 [TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes. Cunningham S; Graham C; Hutchinson M; Droogan A; O'Rourke K; Patterson C; McDonnell G; Hawkins S; Vandenbroeck K Clin Pharmacol Ther; 2005 Dec; 78(6):635-46. PubMed ID: 16338279 [TBL] [Abstract][Full Text] [Related]
9. Association study of promoter polymorphisms of interferon alpha and beta receptor subunit 1 (IFNAR1) gene and therapeutic response to interferon-beta in patients with multiple sclerosis. Hajian S; Mazdeh M; Nouri F; Roshanaei G; Soleimani M Mol Biol Rep; 2021 Aug; 48(8):6007-6013. PubMed ID: 34328599 [TBL] [Abstract][Full Text] [Related]
10. Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Comabella M; Craig DW; Morcillo-Suárez C; Río J; Navarro A; Fernández M; Martin R; Montalban X Arch Neurol; 2009 Aug; 66(8):972-8. PubMed ID: 19667218 [TBL] [Abstract][Full Text] [Related]
11. Single-nucleotide polymorphisms in response to interferon-beta therapy in multiple sclerosis. Vandenbroeck K; Comabella M J Interferon Cytokine Res; 2010 Oct; 30(10):727-32. PubMed ID: 20836710 [TBL] [Abstract][Full Text] [Related]
12. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Byun E; Caillier SJ; Montalban X; Villoslada P; Fernández O; Brassat D; Comabella M; Wang J; Barcellos LF; Baranzini SE; Oksenberg JR Arch Neurol; 2008 Mar; 65(3):337-44. PubMed ID: 18195134 [TBL] [Abstract][Full Text] [Related]
13. IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response. Leyva L; Fernández O; Fedetz M; Blanco E; Fernández VE; Oliver B; León A; Pinto-Medel MJ; Mayorga C; Guerrero M; Luque G; Alcina A; Matesanz F J Neuroimmunol; 2005 Jun; 163(1-2):165-71. PubMed ID: 15885318 [TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms, their allele combinations and IFN-beta treatment response in Irish multiple sclerosis patients. O'Doherty C; Favorov A; Heggarty S; Graham C; Favorova O; Ochs M; Hawkins S; Hutchinson M; O'Rourke K; Vandenbroeck K Pharmacogenomics; 2009 Jul; 10(7):1177-86. PubMed ID: 19604093 [TBL] [Abstract][Full Text] [Related]
16. CCR5 Δ32 and CTLA-4 +49 A/G Gene Polymorphisms and Interferon-β Treatment Response in Croatian and Slovenian Multiple Sclerosis Patients. Nekić J; Stanković Matić I; Rački V; Janko Labinac D; Vuletić V; Kapović M; Ristić S; Peterlin B; Starčević Čizmarević N Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000519 [TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics of the response to IFN-beta in multiple sclerosis: ramifications from the first genome-wide screen. Vandenbroeck K; Matute C Pharmacogenomics; 2008 May; 9(5):639-45. PubMed ID: 18466107 [TBL] [Abstract][Full Text] [Related]
18. Role of differential expression of interferon receptor isoforms on the response of multiple sclerosis patients to therapy with interferon beta. Gilli F J Interferon Cytokine Res; 2010 Oct; 30(10):733-41. PubMed ID: 20874250 [TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomic update on multiple sclerosis: a focus on actual and new therapeutic strategies. Foti Cuzzola V; Palella E; Celi D; Barresi M; Giacoppo S; Bramanti P; Marino S Pharmacogenomics J; 2012 Dec; 12(6):453-61. PubMed ID: 23044601 [TBL] [Abstract][Full Text] [Related]
20. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]